top of page
The Professional Network for Healthcare Experts
Oxford BioDynamics signs first pharmaceutical EpiSwitch Orion agreement with Johnson & Johnson
Oxford BioDynamics has secured its first pharmaceutical-company agreement for the EpiSwitch Orion platform, partnering with Johnson & Johnson on inflammatory bowel disease biomarker discovery.
nuaxia
14 hours ago2 min read
AbbVie licenses Nxera oral inflammatory bowel disease drug in agreement worth up to $1.47 billion
AbbVie has secured exclusive worldwide rights to Nxera Pharma's investigational oral EP4 receptor agonist NXE0033744 for inflammatory bowel disease in a licensing agreement potentially worth $1.47 billion.
nuaxia
2 days ago2 min read
bottom of page